1. Shang Y#, Li S#, Xu T, Sun Y*, Li F*. An optimized platform overcomes excessive tumor immune rejection induced by the CRISPR/Cas9 lentiviral system, Cancer Research 2025 (In press)

2. Cui Y, Qiu T, Wang J, Liu X, Luo Li, Yin Ji, Zhi X, Wang W, Feng G, Wu C, Zhao Z, Zhang H, Li F*, Wu F*, Ren S*. IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC. Molecular Cancer. 2025 Jul; 24(187):1298-1315.

3. Mao S#, Liu X#, Wang L*, Wang Y, Yang S, Jiang T, Li X, Wang Q, Li X, Wu F, Gao G, Chen X, Wu C, Zhang W, Zhang J, Lin X, Zhu X, Li B*, Li F*, Zhou C*, Ren S*. AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC. J Thorac Oncol. 2025 Jun;20(6):739-749.

4. Zhou C#*, Li C#, Luo L#, Li X#, Jia K#, He N, Mao S, Wang W, Shao C, Liu X, Huang K, Yu Y, Cai X, Chen Y, Dai Z, Li W, Yu J, Li J, Shen F, Wang Z, He F, Sun X, Mao R, Shi W, Zhang J, Jiang T*, Zhang Z*, Li F*, Ren S*. Anti-tumor Efficacy of HRS-4642 and Its Potential Combination with Proteasome Inhibition in KRAS G12D-mutant Cancer. Cancer Cell. 2024 Jul;42(7):1286-1300.

5. Huang Q#, Li F#*, Hu H#, Fang Z, Gao Z, Xia G, Ng W, Khodadadi-Jamayran A, Chen T, Deng J, Zhang H, Almonte C, Labbe K, Han H, Geng K, Tang S, Freeman G, Li Y, Chen H*, Wong K*. Loss of TSC1/TSC2 sensitizes immune checkpoint blockage in non-small-cell lung cancer. Science Advances. 2022 Feb 4;8(5):eabi9533.

6. Li F#, Ng W#, Luster T, Hu H, Sviderskiy V, Dowling C, Hollinshead K, Zouitine P, Zhang H, Huang Q, Ranieri M, Wang W, Fang Z, Chen T, Deng J, Zhao K, So H, Khodadadi-Jamayran A, Xu M, Karatza A, Pyon V, Li S, Pan Y, Labbe K, Poirier J, Miller G, Almonte C, Labbe K, Silver H, Rabin A, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman P, Possemato R, Qi J*, Wong KK*. Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer. Cancer Research. 2020 Sep 1;80(17):3556-3567.  (Cover story)

7. Li F, Huang Q, Luster T, Hu H, Zhang H, Ng W, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling C, Bagdatlioglu E, Almonte C, Labbe K, Silver H, Rabin A, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman P, Velcheti V, Freeman G, Qi J, Miller G, Wong KK. In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma. Cancer Discovery. 2020 Feb;10(2):270-287. (Highlighted by Cancer Discovery. 2020 Feb;10(2):179-181.)

8. Li F#, Fang Z#, Zhang J#, Li Chen, Liu H, Xia J, Zhu H, Guo C, Qin Z, Li FM, Han X, Wang Y, Feng Y, Wang Y, Zhang W, Wang Z, Jin Y, Sun Y, Wei W, Zeng R, Chen H, Ji H. Identification of TRA2B-DNAH5 gene fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Research. 2016; 26 (10):1149-1164.

9. Li FM#, Han X#, Li F#, Wang R, Wang H, Gao Y, Wang X, Fang Z, Zhang W, Yao S, Tong X, Wang Y, Feng Y, Sun Y, Li Y, Wong KK, Zhai Q, Chen H*, Ji H*. LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell. 2015. 27(5):698-711. (Cover story)

10. Li F#, Feng Y#, Fang R#, Fang Z, Xia J, Han X, Liu XY, Chen H*, Liu H*, Ji H*. Identification of RET gene fusion by exon array analyses in "pan-negative" lung adenocarcinomas from never smokers. Cell Research. 2012;22(5):928-31.